Stone Helen B, McBride William H, Coleman C Norman
Radiation Research Program, National Cancer Institute, 6130 Executive Boulevard, 6010, Bethesda, Maryland 20892-7440, USA.
Radiat Res. 2002 Feb;157(2):204-23. doi: 10.1667/0033-7587(2002)157[0204:mntdp]2.0.co;2.
Late effects that develop in normal tissues adjacent to the tumor site in the months to years after radiotherapy can reduce the quality of life of cancer survivors. They can be dose-limiting and debilitating or life-threatening. There is now evidence that some late effects may be preventable or partially reversible. A workshop, "Modifying Normal Tissue Damage Postirradiation", was sponsored by the Radiation Research Program of the National Cancer Institute to identify the current status of and research needs and opportunities in this area. Mechanistic, genetic and physiological studies of the development of late effects are needed and will provide a rational basis for development of treatments. Interdisciplinary teams will be needed to carry out this research, including pathologists, physiologists, geneticists, molecular biologists, experts in functional imaging, wound healing, burn injury, molecular biology, and medical oncology, in addition to radiation biologists, physicists and oncologists. The participants emphasized the need for developing and choosing appropriate models, and for radiation dose-response studies to determine whether interventions remain effective at the radiation doses used clinically. Both preclinical and clinical studies require long-term follow-up, and easier-to-use, more objective clinical scoring systems must be developed and standardized. New developments in biomedical imaging should provide useful tools in all these endeavors. The ultimate goals are to improve the quality of life and efficacy of treatment for cancer patients treated with radiotherapy.
放疗后数月至数年,肿瘤部位附近正常组织出现的迟发效应会降低癌症幸存者的生活质量。这些效应可能会限制剂量、使人虚弱甚至危及生命。现在有证据表明,一些迟发效应可能是可预防的或部分可逆的。美国国立癌症研究所放射研究项目主办了一次题为“减轻放疗后正常组织损伤”的研讨会,以确定该领域的现状以及研究需求和机会。需要对迟发效应的发生机制、遗传学和生理学进行研究,这将为开发治疗方法提供合理依据。开展这项研究需要跨学科团队,除了放射生物学家、物理学家和肿瘤学家外,还包括病理学家、生理学家、遗传学家、分子生物学家、功能成像专家、伤口愈合专家、烧伤专家、分子生物学专家和医学肿瘤学家。与会者强调需要开发和选择合适的模型,以及开展辐射剂量反应研究,以确定干预措施在临床使用的辐射剂量下是否仍然有效。临床前研究和临床研究都需要长期随访,必须开发并标准化更易于使用、更客观的临床评分系统。生物医学成像的新进展应能为所有这些工作提供有用的工具。最终目标是提高接受放疗的癌症患者的生活质量和治疗效果。